Get the tools used by (smart)2 investors.
SP500 1.1%DOW 0.9%FTSE 100 0.1%NIKKEI -0.2%OIL 0.3%GOLD 0.4%
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

P/E Ratio

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

111.56
Price
–
Fair Value
–
Upside
92.35 - 120.92
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on 's P/E Ratio:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 20240.0x10.0x20.0x30.0x
Performance Summary
  • Novartis AG ADR's latest twelve months p/e ratio is 18.5x
  • Novartis AG ADR's p/e ratio for fiscal years ending December 2020 to 2024 averaged 21.3x.
  • Novartis AG ADR's operated at median p/e ratio of 20.1x from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Novartis AG ADR's p/e ratio peaked in December 2020 at 30.3x.
  • Novartis AG ADR's p/e ratio hit its 5-year low in December 2022 of 9.2x.
  • Novartis AG ADR's p/e ratio decreased in 2021 (20.1x, -33.7%), 2022 (9.2x, -54.0%), and 2024 (18.5x, -35.4%) and increased in 2020 (30.3x, +1.8%) and 2023 (28.6x, +209.8%).

How does Novartis ADR's P/E Ratio benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Novartis AG ADR because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Novartis ADR P/E Ratio Benchmarks
NameTickerP/E Ratio
Bristol-Myers Squibb CoBRSE:BMY-13.6x
Teva Pharmaceutical Industries LimitedSWX:TEVA-11.3x
Merck & Co., Inc.BRSE:01068305313.9x
HealthcareSECTOR:HLTH.CH16.7x
Novartis AG ADRNYSE:NVS18.5x
Sandoz Group AGSWX:SDZNA
Pfizer IncDB:PFE18.5x
GlaxoSmithKline PLCBRSE:00110265723.8x
Johnson & JohnsonBRSE:00094398127.8x
Roche Holding AGSWX:RO29.6x
AstraZeneca PLCBRSE:00098235233.7x
Eli Lilly and CoSWX:LLY70.5x

Metric Usage: P/E Ratio

Hide this widget
pe_ltm
Slug
number
Datatype
text
Format
current
Default Period
FY, LTM
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to P/E Ratio in the valuation category include:

  • Buyback Yield - A ratio that measures the difference between the amount of share repurchases and the amount of share issuances over the trailing twelve months divided by the company's market capitalization.
  • Price / Operating Cash Flow - Measures the ratio of a stock's price to its operating cash flow per share.
  • 1 Month Price Total Return - The total change in price (adjusted of dividends and splits when applicable) over the last 1 month.
  • Price / LTM FCF - Measures the ratio of a stock's price to its levered free cash flow per share.
View Full List

Search for metric or datapoint

P/E Ratio

Indicates the multiple of earnings that stock investors are willing to pay for one share of the firm.

Definition of P/E Ratio

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-108.7x-48.7x11.3x117.7x2006001,000

The chart above depicts the distribution of p/e ratio for companies operating in the Healthcare sector in the Developed economic region. Over 2,460 companies were considered in this analysis, and 2,366 had meaningful values. The average p/e ratio of companies in the sector is 0.6x with a standard deviation of 20.9x.

Novartis AG ADR's P/E Ratio of 18.5x ranks in the 86.4% percentile for the sector. The following table provides additional summary stats:

P/E Ratio In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,464
Included Constituents2,366
Min-110.2x
Max115.1x
Median-1.4x
Mean0.6x
Standard Deviation20.9x

You can find companies with similar p/e ratio using this stock screener.

All rights reserved. Terms Of Use